Search Results - "Friard, Sylvie"

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer by Derosa, Lisa, Routy, Bertrand, Thomas, Andrew Maltez, Iebba, Valerio, Zalcman, Gerard, Friard, Sylvie, Mazieres, Julien, Audigier-Valette, Clarisse, Moro-Sibilot, Denis, Goldwasser, François, Silva, Carolina Alves Costa, Terrisse, Safae, Bonvalet, Melodie, Scherpereel, Arnaud, Pegliasco, Hervé, Richard, Corentin, Ghiringhelli, François, Elkrief, Arielle, Desilets, Antoine, Blanc-Durand, Felix, Cumbo, Fabio, Blanco, Aitor, Boidot, Romain, Chevrier, Sandy, Daillère, Romain, Kroemer, Guido, Alla, Laurie, Pons, Nicolas, Le Chatelier, Emmanuelle, Galleron, Nathalie, Roume, Hugo, Dubuisson, Agathe, Bouchard, Nicole, Messaoudene, Meriem, Drubay, Damien, Deutsch, Eric, Barlesi, Fabrice, Planchard, David, Segata, Nicola, Martinez, Stéphanie, Zitvogel, Laurence, Soria, Jean-Charles, Besse, Benjamin

“…Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are needed. In a previous…”
Get full text

Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study by Mehlman, Camille, Cadranel, Jacques, Rousseau-Bussac, Gaelle, Lacave, Roger, Pujals, Anaïs, Girard, Nicolas, Callens, Céline, Gounant, Valérie, Théou-Anton, Nathalie, Friard, Sylvie, Trédaniel, Jean, Blons, Hélène, Dujon, Cécile, Duchemann, Boris, Schischmanoff, Pierre Olivier, Chinet, Thierry, Giroux Leprieur, Etienne

“…•We report resistance mechanisms on osimertinib in lung cancer patients.•We analyzed tissue and liquid biopsies collected at progression by NGS.•C797S EGFR…”
Get full text

Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14–skipping mutation: A series of 6 cases by Mayenga, Marie, Assié, Jean-Baptiste, Monnet, Isabelle, Massiani, Marie-Ange, Tabeze, Laure, Friard, Sylvie, Fraboulet, Séverine, Métivier, Anne-Cécile, Chouaïd, Christos, Zemoura, Leïla, Longchampt, Elisabeth, Callens, Céline, Melaabi, Samia, Couderc, Louis-Jean, Doubre, Hélène

“…•46.2 % (6/13) patients with METex14 mutations response to immunotherapy.•Disease control lasted more than 18 months with partial or complete response.•No…”
Get full text

Cost-effectiveness of KRAS , EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study by Loubière, Sandrine, Drezet, Alexandre, Beau-Faller, Michèle, Moro-Sibilot, Denis, Friard, Sylvie, Wislez, Marie, Blons, Hélène, Daniel, Catherine, Westeel, Virginie, Madroszyk, Anne, Léna, Hervé, Merle, Patrick, Mazières, Julien, Zalcman, Gérard, Lacave, Roger, Antoine, Martine, Morin, Franck, Missy, Pascale, Barlesi, Fabrice, Auquier, Pascal, Cadranel, Jacques

“…rearrangement and / mutations constitute the primary biomarkers tested to provide targeted or nontargeted therapies in advanced nonsmall cell lung cancer…”
Get full text

Baseline results of the Depiscan study: A French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR) by Blanchon, Thierry, Bréchot, Jeanne-Marie, Grenier, Philippe A, Ferretti, Gilbert R, Lemarié, Etienne, Milleron, Bernard, Chagué, Dominique, Laurent, François, Martinet, Yves, Beigelman-Aubry, Catherine, Blanchon, François, Revel, Marie-Pierre, Friard, Sylvie, Rémy-Jardin, Martine, Vasile, Manuela, Santelmo, Nicola, Lecalier, Alain, Lefébure, Patricia, Moro-Sibilot, Denis, Breton, Jean-Luc, Carette, Marie-France, Brambilla, Christian, Fournel, François, Kieffer, Alexia, Frija, Guy, Flahault, Antoine

“…Summary Background Lung cancer has the highest mortality-rate per cancer, with an overall 5-year survival <15%. Several non-randomized studies pointed out the…”
Get full text

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer by Costantini, Adrien, Corny, Jennifer, Fallet, Vincent, Renet, Sophie, Friard, Sylvie, Chouaid, Christos, Duchemann, Boris, Giroux-Leprieur, Etienne, Taillade, Laurent, Doucet, Ludovic, Nguenang, Marina, Jouveshomme, Stéphane, Wislez, Marie, Tredaniel, Jean, Cadranel, Jacques

“…Nivolumab for the treatment of advanced nonsmall cell lung cancer (NSCLC) evaluated in phase III trials showed 50% progression at first evaluation, but better…”
Get full text

Real-life experience of ceritinib in crizotinib-pretreated ALK + advanced non-small cell lung cancer patients by Cadranel, Jacques, Cortot, Alexis B, Lena, Hervé, Mennecier, Bertrand, Do, Pascal, Dansin, Eric, Mazieres, Julien, Chouaid, Christos, Perol, Maurice, Barlesi, Fabrice, Robinet, Gilles, Friard, Sylvie, Thiberville, Luc, Audigier-Valette, Clarisse, Vergnenegre, Alain, Westeel, Virginie, Slimane, Khemaies, Buturuga, Alexandru, Moro-Sibilot, Denis, Besse, Benjamin

“…Here we report our experience of ceritinib in crizotinib-pretreated patients with anaplastic lymphoma kinase ( ) positive ( ) non-small cell lung cancer…”
Get full text

Detection of pelvic vein thrombosis by magnetic resonance angiography in patients with acute pulmonary embolism and normal lower limb compression ultrasonography by Stern, Jean-Baptiste, Abehsera, Marc, Grenet, Dominique, Friard, Sylvie, Couderc, Louis-Jean, Scherrer, Antoine, Stern, Marc

“…In patients with proven acute pulmonary embolism (PE), a systematic search for "residual" deep vein thrombosis (DVT) using venography or compression duplex…”
Get more information

Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study by Ferreira, Marion, Swalduz, Aurélie, Greillier, Laurent, du Rusquec, Pauline, Curcio, Hubert, Raimbourg, Judith, Toffart, Anne-Claire, Gounant, Valérie, Couraud, Sebastien, De Chabot, Gonzague, Friard, Sylvie, Hureaux, José, Jeannin, Gaëlle, Odier, Luc, Ricordel, Charles, Wislez, Marie, Descarpentries, Clotilde, Herbreteau, Guillaume, Missy, Pascale, Morin, Franck, Westeel, Virginie, Cortot, Alexis B.

“…•MET exon 14 skipping mutations (METex14) are found in 3% of non-small cell lung cancer (NSCLC) patients.•These patients appear to derive modest benefit from…”
Get full text

Friendly-user score assessing gut dysbiosis and resistance to immune checkpoint inhibitors (ICI) by Derosa, Lisa, Alves Costa Silva, Carolina, Iebba, Valerio, Routy, Bertrand, Reni, Anna, Audigier-Valette, Clarisse, Zalcman, Gerard, Mazieres, Julien, Friard, Sylvie, Goldwasser, François, MORO SIBILOT, Denis Lucien, Scherpereel, Arnaud, Pegliasco, Herve, Martinez, Stéphanie, Escudier, Bernard, Planchard, David, Albiges, Laurence, Besse, Benjamin, Barlesi, Fabrice, Zitvogel, Laurence

“…103 Background: Accumulating evidence pointed to the impact of the intestinal microbiota on ICI outcomes across various cancers. Although specific gut…”
Get full text

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial by Meyer, Guy, Besse, Benjamin, Doubre, Hélène, Charles-Nelson, Anaïs, Aquilanti, Sandro, Izadifar, Armine, Azarian, Reza, Monnet, Isabelle, Lamour, Corinne, Descourt, Renaud, Oliviero, Gérard, Taillade, Laurent, Chouaid, Christos, Giraud, Frederique, Falcoz, Pierre-Emmanuel, Revel, Marie-Pierre, Westeel, Virginie, Dixmier, Adrien, Tredaniel, Jean, Dehette, Stéphanie, Decroisette, Chantal, Prevost, Alain, Pichon, Eric, Fabre, Elizabeth, Soria, Jean-Charles, Friard, Sylvie, Stern, Jean-Baptiste, Jabot, Laurence, Dennewald, Georges, Pavy, Gérard, Petitpretz, Patrick, Tourani, Jean-Marc, Alifano, Marco, Chatellier, Gilles, Girard, Philippe

“…The anti-tumour and anti-metastatic properties of heparins have not been tested in patients with early stage cancer. Whether adjuvant low molecular weight…”
Get full text

High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study by Baldacci, Simon, Figeac, Martin, Antoine, Martine, Descarpentries, Clotilde, Kherrouche, Zoulika, Jamme, Philippe, Copin, Marie-Christine, Tulasne, David, Nanni, Isabelle, Beau-Faller, Michèle, Melaabi, Samia, Levallet, Guénaëlle, Quoix, Elisabeth, Moro-Sibilot, Denis, Friard, Sylvie, Missy, Pascale, Barlesi, Fabrice, Cadranel, Jacques, Cortot, Alexis B

“…MET proto-oncogene (MET) exon 14 splice site (METex14) mutations were recently described in NSCLC and has been reported to correlate with efficacy of MET…”
Get more information

Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study by Akli, Assya, Girard, Nicolas, Fallet, Vincent, Rousseau-Bussac, Gaelle, Gounant, Valérie, Friard, Sylvie, Trédaniel, Jean, Dujon, Cécile, Wislez, Marie, Duchemann, Boris, Giroux-Leprieur, Etienne

“…Background Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used in first line for the treatment of advanced EGFR…”
Get full text

Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome by Derosa, Lisa, Iebba, Valerio, Silva, Carolina Alves Costa, Piccinno, Gianmarco, Wu, Guojun, Lordello, Leonardo, Routy, Bertrand, Zhao, Naisi, Thelemaque, Cassandra, Birebent, Roxanne, Marmorino, Federica, Fidelle, Marine, Messaoudene, Meriem, Thomas, Andrew Maltez, Zalcman, Gerard, Friard, Sylvie, Mazieres, Julien, Audigier-Valette, Clarisse, Sibilot, Denis Moro, Goldwasser, François, Scherpereel, Arnaud, Pegliasco, Hervé, Ghiringhelli, François, Bouchard, Nicole, Sow, Cissé, Darik, Ines, Zoppi, Silvia, Ly, Pierre, Reni, Anna, Daillère, Romain, Deutsch, Eric, Lee, Karla A, Bolte, Laura A, Björk, Johannes R, Weersma, Rinse K, Barlesi, Fabrice, Padilha, Lucas, Finzel, Ana, Isaksen, Morten L, Escudier, Bernard, Albiges, Laurence, Planchard, David, André, Fabrice, Cremolini, Chiara, Martinez, Stéphanie, Besse, Benjamin, Zhao, Liping, Segata, Nicola, Wojcik, Jérôme, Kroemer, Guido, Zitvogel, Laurence

“…The gut microbiota influences the clinical responses of cancer patients to immunecheckpoint inhibitors (ICIs). However, there is no consensus definition of…”
Get more information

Cannabis use and lung cancer: time to stop overlooking the problem? by Betser, Léa, Glorion, Matthieu, Mordant, Pierre, Caramella, Caroline, Ghigna, Maria-Rosa, Besse, Benjamin, Planchard, David, Le Pavec, Jérome, Chapelier, Alain, Friard, Sylvie, Gounant, Valérie, Castier, Yves, Levy, Antonin, Mercier, Olaf, Fabre, Dominique, Fadel, Elie, Pradere, Pauline

Get full text

Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review by Créquit, Perrine, Wislez, Marie, Fleury Feith, Jocelyne, Rozensztajn, Nathalie, Jabot, Laurence, Friard, Sylvie, Lavole, Armelle, Gounant, Valérie, Fillon, Julie, Antoine, Martine, Cadranel, Jacques

“…Crizotinib, an oral tyrosine kinase inhibitor that targets anaplastic lymphoma kinase, has proven to offer sustained progression-free survival in anaplastic…”
Get more information

Intestinal Akkermansia muciniphila predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study by Derosa, Lisa, Routy, Bertrand, Zitvogel, Laurence, Thomas, Andrew M., Zalcman, Gerard, Friard, Sylvie, Mazieres, Julien, Audigier-Valette, Clarisse, Moro-Sibilot, Denis, Goldwasser, Francois, Richard, Corentin, Ghiringhelli, François, Barlesi, Fabrice, Elkrief, Arielle, Alves Costa Silva, Carolina, Planchard, David, Segata, Nicola, Martinez, Stéphanie, Soria, Jean-Charles, Besse, Benjamin

“…Abstract only 9019 Background: The gut microbiome, most specifically centered on one of the most prevalent anaerobic bacterium Akkermansia muciniphila (Akk),…”
Get full text

EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy by Chelabi, Samy, Mignard, Xavier, Leroy, Karen, Monnet, Isabelle, Brosseau, Solenn, Theou-Anton, Nathalie, Massiani, Marie-Ange, Friard, Sylvie, Duchemann, Boris, Fabre, Elizabeth, Giroux-Leprieur, Etienne, Cadranel, Jacques, Wislez, Marie

“…EGFR exon 20 insertions are rare genetic alterations in non-small-cell lung cancers (NSCLCs) that are usually unresponsive to approved EGFR tyrosine kinase…”
Get full text

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in advanced non-small cell lung cancer patients by Derosa, Lisa, Routy, Bertrand, Thomas, Andrew Maltez, Iebba, Valerio, Zalcman, Gerard, Friard, Sylvie, Mazieres, Julien, Audigier-Valette, Clarisse, Moro-Sibilot, Denis, Goldwasser, François, Silva, Carolina Alves Costa, Terrisse, Safae, Bonvalet, Melodie, Scherpereel, Arnaud, Pegliasco, Hervé, Richard, Corentin, Ghiringhelli, François, Elkrief, Arielle, Desilets, Antoine, Blanc-Durand, Felix, Cumbo, Fabio, Blanco, Aitor, Boidot, Romain, Chevrier, Sandy, Daillère, Romain, Kroemer, Guido, Alla, Laurie, Pons, Nicolas, Chatelier, Emmanuelle Le, Galleron, Nathalie, Roume, Hugo, Dubuisson, Agathe, Bouchard, Nicole, Messaoudene, Meriem, Drubay, Damien, Deutsch, Eric, Barlesi, Fabrice, Planchard, David, Segata, Nicola, Martinez, Stéphanie, Zitvogel, Laurence, Soria, Jean-Charles, Besse, Benjamin

“…Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) are needed. We previously…”
Get full text

Lorlatinib – Induced pulmonary arterial hypertension by Chabrol, Alexandre, Mayenga, Marie, Hamid, Abdul Momen, Friard, Sylvie, Salvator, Hélène, Doubre, Hélèe, Fraboulet, Séverine, Metivier, Anne-Cécile, Catherinot, Emilie, Rivaud, Elisabeth, Chaumais, Marie Camille, Montani, David, Couderc, Louis Jean, Tcherakian, Colas

“…•We report here the first cases, to our knowledge, of pulmonary arterial hypertension induced by lorlatinib.•It's first time that a tyrosine kinase inhibitor…”
Get full text